Search results

Selected filters:

Life Sciences
Analysis

Article type

Topic

Sector

Regions

Year

264 results found for your search

Sort options
09 September 2019

Looming Australian IP reforms are a concern for life sciences innovators

Worries about patent eligible subject matter, compulsory licensing and the abolition of innovation patents have been expressed as the country moves closer to re-jigging the system

05 September 2019

China delays foreign patent applications while India gives them priority, study suggests

Recent paper builds on previous work claiming CNIPA ‘bias’ against foreign applicants in sensitive tech areas

04 September 2019

Native American-owned entities are still busy with patents

Assignment records show that assertion-focused North Dakota tribe recently picked up assets formerly owned by Intellectual Ventures and Korean smartphone business Pantech

03 September 2019

Irish Supreme Court decision opens door to interlocutory injunctions

The more flexible test looks set to end the run of adverse decisions that have affected rights holders in one of Europe’s key life sciences hubs

02 September 2019

Sinda may test the market for Chinese IP firm takeovers

A report says the patent filing powerhouse is attracting private equity interest at a possible valuation of around $300 million

30 August 2019

Amgen’s $13.4 billion Otezla purchase shows, once more, the direct financial value of IP in the life sciences space

The Californian company cites US patent protection until 2028 as a key driver of the psoriasis drug acquisition, but antitrust concerns remain

28 August 2019

Gilead set for high-stakes PTAB clash with the US government over HIV patents

The company’s attack on rights held by the Department of Health and Human Services has significant commercial, political and even strategic IP implications

27 August 2019

Armed and dangerous - how patents help Unicorns to fight back

Tech-rich start-ups that do not develop portfolios are vulnerable to attack - as recent Houlihan Lokey analysis of pre-IPO software businesses' IP positions revealed 

26 August 2019

Three key IP takeaways from Bayer's $7.6 billion sale of its animal health unit

The German company's divestiture to Elanco is the latest example of a pharma giant fleeing non-core business areas - and it is unlikely to be the last

23 August 2019

Canon’s portfolio might be shrinking but it’s still world class    

Analysis shows that the Japanese company has cut down its filing activity and ramped up its abandonment rate, while there has been a recent litigation spike, too

23 August 2019

The latest 101 proposal is being held under lock and key but details are leaking out

Sources IAM has spoken to talk of a lengthening document that reflects the scale of the task ahead, while concern remains that a Section 112 problem is in danger of emerging

22 August 2019

Too often Unicorns lack meaningful IP protection and that makes them vulnerable to attack

A billion dollar valuation is all well and good, but many stellar start-ups risk being burned by having to pay-out big money to fend off patent infringement suits

21 August 2019

New written description rule set out by Federal Circuit in precedential Contrave judgment

Appellate court’s decision to uphold patent on weight loss treatment seems to create more flexible requirements.

19 August 2019

For high-cost, high-value patents, fixed-fee procurement could be the answer

A subscription model to cover the application process may well be the best way to make increased expenditure on securing portfolio-enhancing rights more palatable

16 August 2019

AstraZeneca faces increasingly tough evergreening battle in India

A recent Delhi court decision is a reminder of the tight restrictions around species and follow-on patents in the country